Home  >  Press Releases  >  Most Recent
Share

Press Releases

Press release year list 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006
December 20, 2013
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (EST) on Tuesday, Feb. 11, 2014. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Rick Passov will review fourth quarter and full year 2013 financial results, discuss 2014 financial guidance, and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be archived and made available on Feb. 11, 2014. About Zoetis Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, with a focus on both ...
December 19, 2013
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a first quarter dividend payable to holders of the company’s common stock of $0.072 per share, an increase of 11% from the quarterly dividend rate paid in 2013. The dividend is to be paid on Mar. 4, 2014, to holders of record on Jan. 30, 2014. “Since our IPO in February, we have been able to demonstrate the strength of our business model as an independent company and our commitment to generating long-term value for shareholders,” said Zoetis Chief Executive Officer Juan Ramón Alaix. “With the Board’s approval, we are increasing our dividend as we head into 2014 and continuing our commitment to effective and efficient use of our cash.” About Zoetis Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, ...
December 17, 2013
PROHEALTH awarded the largest animal health grant in EU history Zoetis is part of a consortium of 22 academic, industry and private enterprise organizations from 11 countries who are exploring new ways to ensure the sustainability of modern animal production. The consortium was recently awarded the largest animal health grant in EU history. Read the full press release here. ...
December 11, 2013
Today the U.S. Food and Drug Administration finalized Guidance #213 establishing the procedures for voluntarily phasing out growth promotion indications for medically important antibiotics in alignment with Guidance #209 and published proposed changes to the Veterinary Feed Directive (VFD) regulation. The VFD regulation mandates the rules and responsibilities of licensed veterinarians in prescribing and administering medically important antibiotics in feed. Guidance #209 establishes two voluntary principles: The use of medically important antimicrobial drugs in food-producing animals should be limited to uses that are considered necessary for assuring animal health. The use of medically important antimicrobial drugs in food-producing animals should include veterinary oversight or consultation. Guidance #213 provides the procedures for voluntarily phasing out growth promotion indications and establishing therapeutic treatment indications for the use of medically important antimicrobial ...
December 11, 2013
Today the U.S. Food and Drug Administration finalized Guidance #213 establishing the procedures for voluntarily phasing out growth promotion indications for medically important antibiotics in alignment with Guidance #209 and published proposed changes to the Veterinary Feed Directive (VFD) regulation. The VFD regulation mandates the rules and responsibilities of licensed veterinarians in prescribing and administering medically important antibiotics in feed.   Guidance #209 establishes two voluntary principles: The use of medically important antimicrobial drugs in food-producing animals should be limited to uses that are considered necessary for assuring animal health. The use of medically important antimicrobial drugs in food-producing animals should include veterinary oversight or consultation. Guidance #213 provides the procedures for voluntarily phasing out growth promotion indications and establishing therapeutic treatment indications for the use ...
November 26, 2013
Zoetis Inc. (NYSE:ZTS) will participate in the 2013 Bank of America Merrill Lynch Animal Health Summit on Monday, December 16, at the Bank of America Conference Center in Boston, MA. Juan Ramón Alaix, chief executive officer of Zoetis, will represent the company as the keynote speaker and respond to questions from analysts. He is scheduled to present at 12:35 pm. Investors and other interested parties will be able to access the presentation materials by visiting http://investor.zoetis.com/events-presentations after the keynote speech is delivered. About Zoetis Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2012, the company generated annual revenues of $4.3 ...
November 12, 2013
Zoetis Inc. (NYSE:ZTS) will participate in the 25 th Annual Piper Jaffray Healthcare Conference on Tuesday, Dec. 3, at the New York Palace Hotel in New York City. Rick Passov, executive vice president and chief financial officer of Zoetis, will represent the company as a speaker and respond to questions from analysts. He is scheduled to present at 11:30 a.m. (ET) Investors and other interested parties may register and access the live webcast by visiting the Conference website, http://www.media-server.com/m/p/zu6pbsco, at 11:30 a.m. (ET). on Dec. 3, 2013. About Zoetis Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2012, the company generated annual revenues of $4.3 ...
November 5, 2013
Third Quarter 2013 Revenue of $1.1 Billion Increased 8% Compared to Third Quarter 2012 Third Quarter 2013 Reported Net Income of $131 Million, or Diluted EPS of $0.26, Decreased 19%, Compared to Third Quarter 2012 Third Quarter 2013 Adjusted Net Income of $172 Million, or Adjusted Diluted EPS 1 of $0.34, Increased 12% and 10%, Respectively, Compared to Third Quarter 2012 Narrows Full-Year 2013 Adjusted Diluted EPS 1 Guidance to $1.38 - $1.42 Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2013. The company reported revenue of $1.1 billion for the third quarter of 2013, an increase of 8% from the third quarter of 2012. Revenue reflected an operational 2 increase of 9%, with foreign currency having a negative impact of 1 percentage point. Net income for the third quarter of 2013 was $131 million, or $0.26 per diluted share, a decrease of 19%, compared to the third quarter of 2012. Adjusted net income1 for the third quarter of 2013 was $172 million, ...
October 28, 2013
Zoetis Inc. (NYSE:ZTS) today announced that it has extended until Oct. 30, 2013 at 5:00 p.m., New York City time, the expiration date of its offer to exchange: $400,000,000 aggregate principal amount of its unregistered 1.150% Senior Notes due 2016 (the “2016 unregistered notes”) for a like principal amount of its 1.150% Senior Notes due 2016 that have been registered under the Securities Act of 1933; $750,000,000 aggregate principal amount of its unregistered 1.875% Senior Notes due 2018 (the “2018 unregistered notes”) for a like principal amount of its 1.875% Senior Notes due 2018 that have been registered under the Securities Act of 1933; $1,350,000,000 aggregate principal amount of its unregistered 3.250% Senior Notes due 2023 (the “2023 unregistered notes”) for a like principal amount of its 3.250% Senior Notes due 2023 that have been registered under the Securities Act of 1933; and $1,150,000,000 aggregate principal amount of its unregistered 4.700% Senior Notes due 2043 (the ...
October 22, 2013
“Animal Connections” Rolls in to Washington, D.C.  Oct. 26-29 From the cows that provide the milk for a bowl of cereal to the deer nibbling on a shrub in the park, from sea lions working with their trainers at the zoo to puppies chasing balls in the yard, the connections humans have with animals are vast. This special relationship is explored in a new mobile exhibit from the Smithsonian. “Animal Connections: Our Journey Together,” a custom-built exhibition housed on an 18-wheel truck that expands into 1,000 square feet of space, will be on view on the National Mall between the Smithsonian Castle and the Smithsonian’s National Museum of Natural History Saturday, Oct. 26, through Monday, Oct. 28, before moving to a location near the U.S. Botanic Garden Tuesday, Oct. 29. The free exhibition will be open daily from 10 a.m. to 4 p.m.  For the safety of animals and people, visitors are asked not to bring pets. “The affection that people everywhere have for animals sparked our enthusiasm for ...
October 1, 2013
FLORHAM PARK, N.J., October 1, 2013 – Zoetis Inc., (NYSE: ZTS) formerly the animal health business unit of Pfizer Inc., has notified the U.S. Food and Drug Administration (FDA) that the company will voluntarily withdraw the marketing authorizations (New Animal Drug Applications) for 3-Nitro (roxarsone)  and Carb-O-Sep ® (carbarsone). The decision to withdraw the marketing authorization for 3-Nitro, a feed medicine containing the organic arsenical roxarsone, follows the suspension of U.S.sales of this product, on July 8, 2011.  Zoetis suspended sales at the request of the FDA based on a study conducted by the Agency.  The study used a new method of testing for very low levels of inorganic arsenic in poultry tissue.  It suggested that the use of 3-Nitro resulted in extremely low residue levels of inorganic arsenic in the liver of treated chickens.  This extremely low level was equivalent to the amount of inorganic arsenic found in an eight-ounce glass of drinking water. Zoetis no longer ...
September 30, 2013
Zoetis Inc. (NYSE:ZTS), formerly the animal health business unit of Pfizer Inc., will host a webcast and conference call at 8:30 a.m. (EST) on Tuesday, Nov. 5, 2013. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Rick Passov will review third-quarter 2013 financial results, discuss 2013 financial guidance, and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be archived and made available on Nov. 5, 2013. About Zoetis Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary ...
September 19, 2013
Zoetis Offers a Targeted Approach that Rapidly, Sustainably and Safely Breaks the Cycle of Itch and Inflammation Associated with Allergic Skin Diseases in Dogs FLORHAM PARK, N.J. – September 19, 2013 – Zoetis, Inc. (NYSE: ZTS), formerly the animal health business unit of Pfizer Inc., today announced that following a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP), the European Commission has approved APOQUEL ® (oclacitinib tablet) in the European Union for the treatment of pruritus associated with allergic dermatitis and the treatment of clinical manifestations of atopic dermatitis in dogs at least 12 months of age. Developed by Zoetis, APOQUEL ® is the first Janus kinase (JAK) inhibitor approved for veterinary use. It inhibits the function of a variety of allergic, itch and pro-inflammatory cytokines dependent on JAK enzyme activity and thus stops the cycle of itch and inflammation occurring in skin allergies. APOQUEL ® provides rapid and ...
September 16, 2013
Governor Chris Christie and Zoetis Leaders Plant Red Oak, State Tree of New Jersey Addresses 400+ Zoetis Employees Zoetis Inc. (NYSE: ZTS), formerly the animal health business unit of Pfizer Inc., today celebrated establishing strong roots in New Jersey by hosting New Jersey Governor Chris Christie for an address to employees at the company’s new world headquarters in Florham Park, N.J. Governor Christie joined members of the Zoetis Executive Team to plant a Red Oak, the New Jersey state tree, helping replace trees lost to Super Storm Sandy. “The celebration and tree-planting is another important step for Zoetis in our first year as an independent public company,” said Sandra J. Beaty, Executive Vice President, Corporate Affairs at Zoetis. “We are committed to growing our business in New Jersey where we have access to a highly educated and diverse workforce, which is essential to managing a global animal health company. We want to thank Governor Chris Christie, Lieutenant Governor Kim ...
September 12, 2013
The Board of Directors of Zoetis Inc. (NYSE:ZTS), formerly the animal health business of Pfizer Inc., has declared a fourth-quarter dividend payable to holders of the company’s common stock of $0.065 per share. The dividend is to be paid on Dec. 2, 2013, to holders of record on Nov. 1, 2013. About Zoetis Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2012, the company generated annual revenues of $4.3 billion. With approximately 9,300 employees worldwide at the beginning of 2013, Zoetis has a local presence in approximately 70 countries, including 29 manufacturing facilities in 11 countries. Its products serve veterinarians, livestock producers and people who raise ...
August 16, 2013
“Animal Connections” Rolls in to Newark’s Prudential Center August 19-21 and Morristown’s Fosterfields September 8 NEWARK, N.J. August 16, 2013 —From the cows that provide the milk for a bowl of cereal to the deer nibbling on a shrub in the park, from sea lions working with their trainers at the zoo to puppies chasing balls in the yard, the connections humans have with animals are vast. This special relationship is explored in a new mobile exhibition from the Smithsonian. “Animal Connections: Our Journey Together,” a custom-built exhibition housed on an 18-wheel truck that expands into 1,000 square feet of space, will be at the Prudential Center in Newark August 19 through August 21, and at the 1920s Country Fair and Harvest Festival at Fosterfields Living Historical Farm in Morristown on September 8.The exhibition is an introduction to the world of veterinary medicine and was developed to inspire future generations of veterinary professionals.  This free exhibition explores the ...
August 6, 2013
Second Quarter 2013 Revenue of $1.11 Billion Increased 2% Compared to Second Quarter 2012 Second Quarter 2013 Reported Net Income of $128 Million, or Diluted EPS of $0.26, Decreased 26%, Compared to Second Quarter 2012 Second Quarter 2013 Adjusted Net Income of $178 Million, or Adjusted Diluted EPS 1 of $0.36, Increased 1% and 3%, respectively, Compared to Second Quarter 2012 Reaffirms Full-Year 2013 Adjusted Diluted EPS 1 Guidance of $1.36 - $1.42 Zoetis Inc. (NYSE: ZTS), a former business unit of Pfizer Inc., today reported its financial results for the second quarter of 2013. The company reported revenue of $1.11 billion for the second quarter, an increase of 2% from the second quarter of 2012. Revenue reflected an operational 2 increase of 4%, with foreign currency having a negative impact of 2 percentage points. Net income for the second quarter of 2013 was $128 million, or $0.26 per diluted share, a decrease of 26%, compared to the second quarter of 2012. Adjusted net income1 ...
August 5, 2013
First vaccine from JV established to develop and manufacture animal vaccines in China Zoetis today announced that its joint venture in China received the approval by the Ministry of Agriculture of the People’s Republic of China for Rui Lan An™, a specialized vaccine to help control the highly pathogenic porcine reproductive and respiratory syndrome (HP PRRS). Rui Lan An, which will be launched later this month, is the first vaccine to emerge from the joint venture that was established to develop and manufacture animal vaccines specifically designed to answer the needs of China’s livestock producers. It will help China’s pork producers meet increasing demand in China for quality, affordable pork. “Our innovation starts with our customers and an understanding of their everyday animal health challenges. Rui Lan An exemplifies the commitment of our joint venture to develop and manufacture quality vaccines well matched to the local health challenges facing China’s pork industry,” said ...
August 1, 2013
Zoetis Inc. (NYSE: ZTS), a former business unit of Pfizer Inc., today announced the appointment of Louise M. Parent, Executive Vice President and General Counsel of American Express Company, to its Board of Directors. Ms. Parent will serve on the Compensation Committee of the Board. Ms. Parent has deep experience in corporate governance and board matters, gained during her tenure with American Express, where she works extensively with the Audit, Compensation, and Nomination and Governance committees in her role as General Counsel. Ms. Parent also has served on the operating committee and global management team of American Express for the last 10 years and as a member of the board of American Express Centurion Bank. She recently announced her retirement from American Express after a 36-year career with the global services company. As a well-respected general counsel and leader at American Express, Ms. Parent brings perspectives that will be crucial as Zoetis becomes a fully independent ...
July 10, 2013
Biotechnology and Biological Sciences Research Council grant supports food safety study FLORHAM PARK, N.J., July 10, 2013 — Zoetis Inc., formerly the animal health business unit of Pfizer Inc., and The Roslin Institute at the University of Edinburgh, United Kingdom, today announced a collaboration for research of Salmonella in cattle. The Roslin Institute has received funding from the Biotechnology and Biological Sciences Research Council (BBSRC) to support collaborative research with Zoetis that will bring valuable industry knowledge and input into its academic research program. For three years, the BBSRC will contribute 80 percent of funding for the study — close to $1 million — and Zoetis will not only provide the remaining 20 percent of funding but also provide in-kind services via research materials and expertise. Researchers at The Roslin Institute and Zoetis will jointly investigate how Salmonella enters and persists within the bovine lymphatic system and can lead to ...
July 8, 2013
USDA Agricultural Marketing Service verifies IMPROVEST® Quality Management System for on-farm procedures USDA Food Safety and Inspection Service confirms IMPROVEST-managed hogs arriving to a packing plant with proper certification should be classified as barrows by inspectors FLORHAM PARK, N.J., July 8, 2013 – U.S. pork producers and the packers that harvest the meat they produce now have the added assurance that the U.S. Department of Agriculture (USDA) has approved two processes regarding the use of IMPROVEST® (gonadotropin releasing factor analog – diphtheria toxoid conjugate).  IMPROVEST, an immunological product, is approved by the U.S. Food and Drug Administration (FDA) for the temporary immunological castration and reduction of boar taint* in intact male pigs intended for slaughter. “The use of IMPROVEST is a major shift for the entire pork chain, and we voluntarily sought these extra approvals to help ensure that our customers have the utmost confidence using IMPROVEST,” said ...
July 2, 2013
Zoetis Inc. (NYSE: ZTS), formerly the animal health business unit of Pfizer Inc., announced plans to expand its manufacturing facility in Lincoln, Neb., to facilitate the production of high-quality, reliable medicines for veterinarians, livestock producers and the animals under their care. A world leader in animal health, Zoetis expects this expansion to affirm its longstanding commitment to being a world-class manufacturer of animal health products as well as to continue to be an employer of choice in Lincoln. The plan calls for a 19,000 square-foot, three-story expansion of the existing production facility to accommodate the transfer of products from a third-party manufacturer to Lincoln. Early stages of planning and construction have begun and groundbreaking is expected to occur later this summer, initiating the start of the full construction phase. Zoetis expects to complete construction in 2014. This expansion will help ensure a reliable, consistent supply of quality medicines ...
July 1, 2013
Contribution of $100,000 will support continued education of veterinarians in swine research FLORHAM PARK, N.J., July 1, 2013 —In an effort to help strengthen educational programs that impact the future of animal agriculture research and development, Zoetis announced today a three-year Pork Research Fellowship program with the College of Veterinary Medicine at Iowa State University (ISU).  Zoetis will contribute $100,000 to support the tuition of three students who are eager to continue their education in veterinary swine research. “There is an ongoing critical need for new scientists focused on swine research necessary to advance this area of veterinary medicine and prevent diseases that can impact humans,” said Michelle Haven, PhD, senior vice president, Corporate Development, Alliances and Solutions, Zoetis.  “We hope this fellowship presents young researchers with opportunities and experiences for vibrant research careers in veterinary medicine.” To complement the formal education ...
June 28, 2013
Zoetis Inc. (NYSE: ZTS), formerly the animal health business of Pfizer Inc., will host a webcast and conference call at 8:30 a.m. (EDT) on Tuesday, Aug. 6, 2013. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Rick Passov will review second-quarter 2013 financial results, discuss 2013 financial guidance, and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be archived and made available on Aug. 6, 2013. About Zoetis Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines ...
June 24, 2013
Names Michael McCallister as Non-Executive Chairman of the Board Appoints Two New Board Members, Sanjay Khosla and Robert Scully Zoetis Inc. (NYSE: ZTS), the former animal health business of Pfizer Inc. (NYSE: PFE), opens a new chapter in the company’s history today, marking its separation from Pfizer and first day as a fully independent company. “This is an historic day for Zoetis,” said Zoetis Chief Executive Officer Juan Ramón Alaix. “We are setting off on the next stage in our company’s life – pursuing our own initiatives and strategies as a fully independent company.” “I am very proud of all the Zoetis colleagues who have prepared us for this day, while continuing to support our customers with the products, innovations and reliable supply they expect from us. We will continue serving our customers in ways that make a meaningful difference to their businesses and strengthen our position as the world leader in animal health,” said Alaix. As of today, according to the terms of the ...
June 20, 2013
The Board of Directors of Zoetis Inc. (NYSE: ZTS), formerly the animal health business of Pfizer Inc., has declared a third-quarter dividend payable to holders of the company’s common stock of $0.065 per share. The dividend is to be paid on Sept. 2, 2013, to holders of record on Aug. 1, 2013. About Zoetis Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, with a focus on both farm and companion animals. The company generated annual revenues of $4.3 billion in 2012. It has more than 9,300 employees worldwide and a local presence in approximately 70 countries, including 29 manufacturing facilities in 11 countries. Its products serve veterinarians, livestock producers and people who raise and care for farm and companion animals in 120 countries. DISCLOSURE NOTICE: ...
June 6, 2013
Thailand to be positioned as epicenter for progress of the animal health industry BANGKOK, THAILAND - Zoetis Inc., formerly the animal health business unit of Pfizer Inc., is organizing a Congress with more than  1,000 animal health industry professionals to map out a strategy that will put Thailand in the forefront of  ASEAN’s animal health sector. Professionals involved in veterinary science, including academics, veterinarians, farm owners, professionals in the livestock sector, as well as technicians and manufacturers of equipment related to animal health will develop a blueprint for the growth of the animal health industry in Thailand. The ‘Zoetis Congress for Animal Health’ will be held at CentralWorld Centara, Bangkok on June 10, 2013. Songwut Sakchalathorn, General Manager, Zoetis (Thailand) Ltd., said, “The ASEAN Economic Community’s focus on economic development in the region gives Thailand a historic opportunity to become the center of the animal health industry in ASEAN.” ...
June 3, 2013
Researchers to examine the effects of animal-assisted therapy on pediatric oncology patients, their primary caregivers, and therapy dogs at two major children’s hospitals across the country WASHINGTON, D.C. – Help for the more than 12,000 children diagnosed with cancer each year in the United States, in the form of an innovative, four-legged therapy, is about to be rigorously studied to determine its efficacy. Zoetis Inc., a global leader in the advancement of animal health and wellness, and American Humane Association, which since 1877 has been the nation’s leading charity dedicated to the  welfare, wellness and well-being of children and animals, and to unleashing the full potential of the bond between humans and animals to the mutual benefit of both, are announcing the beginning of the pilot trial at sites in Florida and Tennessee of a groundbreaking  research study on the effects of animal-assisted therapy on pediatric oncology patients and their families. The Canines and ...
May 30, 2013
Comprehensive eCommerce website creates personal shopping experience for veterinary professionals Finding time in a hectic veterinary practice to order animal health products from Zoetis just became faster and easier, thanks to a new web-based ordering site that offers customers in the United States 24/7 access to more than 300 product lines that support the health of beef and dairy cattle, poultry, pigs, dogs, cats, horses and sheep. The new eCommerce site ( www.zoetisus.com click on SHOP)—the industry’s most robust and personalized web-based ordering system of its kind—features a personalized home page that creates a seamless interaction between Zoetis and its customers, displaying recent order history, product preferences, and promotions specific to the user’s practice. “Customers can still expect the same level of interaction and support from their Zoetis representative. However, the eCommerce site will now provide the added convenience of 24/7 online access to help our customers ...
May 22, 2013
Zoetis Inc. (NYSE: ZTS) announced it intends to file a Registration Statement on Form S-4 with the Securities and Exchange Commission (SEC) today in connection with the proposed exchange offer announced by Pfizer Inc. (NYSE: PFE). As part of the offer, Pfizer shareholders will be able to exchange all, some or none of their shares of Pfizer common stock for shares of Zoetis common stock. Pfizer currently holds approximately 80% of the outstanding common stock of Zoetis. If the exchange offer is fully subscribed, Pfizer will no longer have a controlling ownership interest in Zoetis, and Zoetis will become a fully independent company upon completion of the exchange offer. If the exchange offer is undersubscribed, Pfizer would distribute less than 400,985,000 shares of Zoetis common stock. In that case, Pfizer would continue to own an interest in Zoetis and, depending on the number of shares of Zoetis common stock distributed in the exchange offer, Pfizer could retain voting control of ...
May 20, 2013
MADISON, NJ - May 20, 2013 –Zoetis Inc. (NYSE: ZTS) acknowledges that the European Commission started a procedure under Article 45 of Regulation (EC) No. 726/2004 regarding the EU marketing authorization for Suvaxyn PCV, a centrally-authorized vaccine against Porcine Circovirus 2 in swine. As part of this procedure, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Veterinary Use (CVMP) discussed the issue during its latest monthly meeting (14-16 May 2013) . The initiation of the above procedure follows Zoetis’ proactive decision, on 25 March 2013, to stop the distribution of two batches of Suvaxyn PCV as a result of higher than expected adverse reactions, reported mainly in Spain. The two batches were later recalled by Zoetis, following subsequent discussions with the Spanish authorities and the EMA. Zoetis continues to investigate the potential root cause for the reported adverse reactions and is committed to working with the EMA, the European Commission, ...
May 20, 2013
$100,000 gift will help advance food safety for consumers Zoetis Inc., formerly the animal health business unit of Pfizer, today announced a gift of $100,000 for Salmonella research to Texas Tech University, College of Agricultural Sciences and Natural Resources, Department of Animal and Food Sciences. The research gift will help provide resources to better understand and describe the ecology of Salmonella in cattle populations and to discover and evaluate tools that might ultimately result in a safer food supply. “We believe food-safety research is critical to the current and future health of the cattle industry,” said Rob Kelly, vice president, U.S. Cattle and Equine Business Unit at Zoetis. “Consumers expect the food they serve their families to be wholesome and safe, and they are counting on everyone in the industry to work together to deliver safe food to families around the world.” Establishing partnerships with top research institutions such as Texas Tech University is ...
May 16, 2013
Zoetis Offers a Targeted New Approach to Rapidly and Safely Stop the Cycle of Itch and Inflammation Associated with Allergic Skin Disease in Dogs Zoetis, Inc. (NYSE: ZTS), formerly the animal health business unit of Pfizer Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved APOQUEL® (oclacitinib tablet) for the control of pruritus associated with allergic dermatitis and the control of atopic dermatitis in dogs at least 12 months of age. Pruritus, or itching, is the most common sign of allergies in dogs. Developed by Zoetis, APOQUEL is the first Janus kinase (JAK) inhibitor approved for veterinary use that targets the itch and inflammation pathway. APOQUEL provides fast-acting relief from itching and improves inflammation for the estimated 8.2 million dogs that suffer from short- and long-term allergic skin conditions. “Previously available treatments have helped with the management of allergic skin disease in dogs, but an unmet need still exists for a ...
April 30, 2013
First-Quarter 2013 Revenues of $1.09 Billion Increased 4% Compared to First Quarter 2012 First-Quarter 2013 Reported Net Income of $140 Million, or Diluted EPS of $0.28, Increased 26% and 27%, respectively, Compared to First Quarter 2012 First-Quarter 2013 Adjusted Net Income 1 of $179 Million, or Adjusted Diluted EPS 1 of $0.36, Increased 18% and 20%, respectively, Compared to First Quarter 2012 Company Provides Full-Year 2013 Adjusted Diluted EPS 1 Guidance of $1.36 - $1.42 Zoetis TM (NYSE: ZTS), formerly the animal health business of Pfizer Inc., today reported its financial results for the first quarter of 2013. The company reported revenues of $1.09 billion for the first quarter, an increase of 4% from the first quarter of 2012. Revenues reflected an operational 2 increase of 5%, with foreign currency having a negative impact of 1%. Net income for the first quarter of 2013 was $140 million, or $0.28 per diluted share, an increase of 26% and 27%, respectively, compared to the ...
April 18, 2013
Two awards presented to support research in otitis and atopic dermatitis Zoetis Inc., formerly the animal health business unit of Pfizer Inc., today announced the first recipients of the company’s Excellence in Dermatology™ Research Grant program. The objective of the new program is to support research in the area of basic science diagnosing and treating dermatologic conditions in dogs and cats. Investigators from the University of Pennsylvania and Johns Hopkins University will receive one grant to pursue collaborative research in Pseudomonas otitis in dogs. A second grant is being awarded to a team at the University of Minnesota to study the potential for a new drug target in atopic dermatitis. “Zoetis is committed to the advancement of clinical science and the improvement of care in the field of companion animal dermatology,” said J. Michael McFarland, DVM, DABVP and group director of Companion Animal Veterinary Operations for Zoetis. “We are pleased to support these research ...
April 15, 2013
Product Features Advanced Sensitivity ZoetisTM, formerly the animal health business unit of Pfizer Inc., today announced the U.S. Department of Agriculture (USDA) has approved a newly-enhanced version of the WITNESS® HW Heartworm Antigen Test kit for dogs and cats. Launched today, the enhanced WITNESS HW test kit is now available to veterinarians nationwide. Enhancements to the biologics, including test antibodies, improvements to the buffer and sample pad and improve the signal strength at the control line for better confidence in the results, translates to improved sensitivity in the convenient, affordable and versatile test. “Veterinarians have depended on WITNESS HW since its introduction in 1997,” said J. Michael McFarland, DVM, DABVP and group director of Companion Animal Veterinary Operations for Zoetis. “The enhanced version of this trusted product provides veterinarians with accurate, easy to interpret results in approximately ten minutes so they can begin heartworm ...
March 28, 2013
The Board of Directors of Zoetis TM (NYSE: ZTS), formerly the animal health business of Pfizer Inc., has declared a second-quarter dividend payable to holders of the company’s Class A common stock and Class B common stock of $0.065 per share. The dividend is to be paid on June 6, 2013, to holders of record on May 1, 2013. About Zoetis Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, with a focus on both farm and companion animals. The company generated annual revenues of $4.3 billion in 2012. It has more than 9,300 employees worldwide and a local presence in approximately 70 countries, including 29 manufacturing facilities in 11 countries. Its products serve veterinarians, livestock producers and people who raise and care for farm and companion animals in 120 ...
March 26, 2013
Zoetis TM (NYSE: ZTS), formerly the animal health business of Pfizer Inc., will host a webcast and conference call at 8:30 a.m. (EDT) on Tuesday, April 30, 2013. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Rick Passov will review first-quarter 2013 financial results, discuss 2013 financial guidance, and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://www.zoetis.com/events-and-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be archived and made available on April 30. About Zoetis Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines and ...
March 22, 2013
Zoetis, formerly Pfizer Animal Health, announces the return of the Cattle Call grant program and is accepting research proposals for improving cattle reproduction or developing models for managing cattle pain. The Cattle Call supports the development of new products and services that improve the health and productivity of beef and dairy cattle. In 2013, Zoetis will fund one or more researchers with a grant of up to $150,000, with minimum funding of $25,000. “The inaugural Cattle Call grant program in 2012 successfully brought forth many new ideas and technologies that are helping to address important needs in the veterinary and cattle industries,” says Michelle Haven, PhD, senior vice president, corporate development, alliances and solutions, Zoetis. “We are very excited about the research we helped fund for improving productivity and immune function in cattle, and we look forward to building on our partnerships to expand research into reproduction and pain management in 2013.” ...
February 6, 2013
Zoetis TM (NYSE:ZTS), formerly the animal health business unit of Pfizer Inc., today announced the closing of its previously announced initial public offering. The offering of 99,015,000 shares of its Class A common stock included 12,915,000 shares of Class A common stock that were sold pursuant to the underwriters’ option to purchase additional shares, which was exercised in full prior to the closing. Zoetis did not receive any of the proceeds of the offering. Following the completion of the initial public offering, Pfizer owns 100% of the outstanding Class B common stock of Zoetis and retains an approximately 80% ownership of Zoetis. J.P. Morgan, BofA Merrill Lynch and Morgan Stanley served as joint lead book-running managers for the offering. Barclays, Citigroup, Credit Suisse, Deutsche Bank Securities, Goldman, Sachs & Co., Guggenheim Securities and Jefferies served as book-running managers for the offering. BNP PARIBAS, HSBC, Loop Capital Markets, RBC Capital Markets, The ...
January 31, 2013
MADISON, N.J.-ZoetisTM, formerly the animal health business unit of Pfizer Inc., today announced the pricing of its initial public offering of 86,100,000 shares of its Class A common stock at $26 per share. The shares are expected to begin trading tomorrow, Feb. 1, on the New York Stock Exchange under the symbol “ZTS.” Zoetis will not receive any of the proceeds of the offering. Following the completion of the initial public offering, Pfizer will own 100% of the outstanding Class B common stock of Zoetis and will retain an approximately 83 percent ownership of Zoetis. The underwriters also have an option to purchase up to an additional 12,915,000 shares of Class A common stock. Zoetis will not receive any of the proceeds from any shares sold pursuant to this option. If the underwriters exercise this option in full, Pfizer is expected to retain an approximately 80 percent ownership of Zoetis. J.P. Morgan, BofA Merrill Lynch and Morgan Stanley served as joint lead book-running managers ...